Healthcare > Pharmaceuticals & Biotechnology
•2438 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2438)
| Company | Market Cap | Price |
|---|---|---|
|
KMDA
Kamada Ltd.
Inhaled Alpha-1 Antitrypsin therapy for AATD places Kamada in rare-disease biotech therapeutics.
|
$390.86M |
$6.81
+0.15%
|
|
LCTX
Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics' core business is developing allogeneic cell therapy platforms and products (OpRegen, OPC1, ReSonance ANP1).
|
$390.49M |
$1.73
-0.86%
|
|
YMAB
Y-mAbs Therapeutics, Inc.
Company operates oncology-focused biotechnology with immunotherapy assets.
|
$389.89M |
$8.61
|
|
ITOS
iTeos Therapeutics, Inc.
iTeos Therapeutics is a biotech company focused on oncology, developing cancer immunotherapies.
|
$388.48M |
$10.15
|
|
TRDA
Entrada Therapeutics, Inc.
Entrata's primary value proposition is its Drug Delivery Platform (EEV) enabling intracellular delivery of therapeutics.
|
$383.41M |
$10.10
-0.25%
|
|
VIGL
Vigil Neuroscience, Inc.
Direct product: Vigil's lead program iluzanebart is a fully human monoclonal antibody TREM2 agonist, categorizing under Monoclonal Antibody Therapeutics.
|
$375.71M |
$8.05
|
|
NWBO
Northwest Biotherapeutics, Inc.
NWBO is a cancer-focused biotechnology company developing oncology immunotherapies (DCVax) and related products; tags align with Biotech - Oncology.
|
$374.29M |
$0.25
|
|
NMRA
Neumora Therapeutics, Inc. Common Stock
Company focuses on neuropsychiatric drug development, including navacaprant for major depressive disorder, aligning with Neuropsychiatric Drug Development.
|
$370.86M |
$2.30
+2.22%
|
|
GALT
Galectin Therapeutics Inc.
Lead cancer therapy program belapectin demonstrates oncology-focused Biotech activity and immuno-oncology potential.
|
$368.99M |
$5.75
+0.70%
|
|
ANRO
Alto Neuroscience, Inc.
Company focuses on Neuropsychiatric drug development across MDD, bipolar depression, TRD, and schizophrenia using precision psychiatry.
|
$365.81M |
$13.56
+1.50%
|
|
AUTL
Autolus Therapeutics plc
Core product: obe-cel CAR-T cell therapy (cell therapy) for rr B-ALL.
|
$364.61M |
$1.37
-1.44%
|
|
CLLS
Cellectis S.A.
Lead assets UCART22 and UCART20x22 are allogeneic cell therapies (CAR-T) directly developed and manufactured by the company.
|
$363.35M |
$5.07
-3.24%
|
|
AHG
Akso Health Group
Cancer therapy/oncology biotech focus and planned oncology centers.
|
$359.50M |
$1.46
-3.31%
|
|
RCKT
Rocket Pharmaceuticals, Inc.
Direct gene therapy platform encompassing ex vivo LV and in vivo AAV modalities.
|
$355.00M |
$3.30
+6.45%
|
|
OCGN
Ocugen, Inc.
Ocugen's modifier gene therapy platform and lead retinal candidates (OCU400/OCU410) are gene therapy products targeting vision disorders.
|
$344.92M |
$1.19
+1.71%
|
|
QTRX
Quanterix Corporation
Offers contract research services via its Accelerator Lab, aligning with CRO-type activities.
|
$342.92M |
$7.38
+2.07%
|
|
BNTC
Benitec Biopharma Inc.
BB-301 is an AAV-based gene therapy leveraging gene silencing and wildtype replacement, aligning with Gene Therapy.
|
$341.65M |
$13.05
+0.93%
|
|
DCTH
Delcath Systems, Inc.
Delcath's core offering is a Drug Delivery Platform enabling hepatic delivery of chemotherapy (PHx/HEPZATO KIT) for liver-directed treatment.
|
$337.22M |
$9.63
+4.39%
|
|
BIOA
BioAge Labs, Inc.
BioAge's lead program BGE-102 is an oral small-molecule therapeutic, and APJ agonists are being developed for obesity, fitting the 'Oral Small Molecule Therapeutics' investable theme.
|
$335.20M |
$9.34
+3.72%
|
|
ALDX
Aldeyra Therapeutics, Inc.
Lead reproxalap for dry eye disease is an ophthalmic drug, representing a direct product in ophthalmology.
|
$334.82M |
$5.59
+6.27%
|
|
KYTX
Kyverna Therapeutics, Inc.
KYTX's lead and pipeline CAR-T products (KYV-101, KYV-102, KYV-201) are autologous/allogeneic CD19 CAR-T cell therapies, a direct cell therapy product category.
|
$332.13M |
$7.67
+3.86%
|
|
AMRN
Amarin Corporation plc
Amarin's flagship product VASCEPA/icosapent ethyl is a cardiovascular drug indicated to reduce major adverse cardiovascular events when added to statin therapy, making 'Cardiovascular Drugs' a core category.
|
$331.95M |
$16.09
+2.35%
|
|
AVXL
Anavex Life Sciences Corp.
Company's lead product and pipeline consist of oral small-molecule therapeutics (ANAVEX 2-73 and ANAVEX 3-71).
|
$331.55M |
$3.87
+11.85%
|
|
CNFN
CFN Enterprises Inc.
CNFN's Ranco segment operates as a contract manufacturer/co-packer and white-label producer for clients.
|
$331.15M |
$2.79
|
|
SOPH
SOPHiA GENETICS S.A.
Companion Diagnostics: enables biomarker-driven diagnostic support for therapy selection.
|
$327.54M |
$4.92
+2.18%
|
|
PYXS
Pyxis Oncology, Inc.
Pyxis Oncology is a biotechnology company focused on oncology therapeutics, with MICVO as its lead asset in cancer.
|
$327.46M |
$5.29
-1.03%
|
|
TLSI
TriSalus Life Sciences, Inc.
Core PEDD drug-delivery platform technology powering TriNav systems.
|
$322.64M |
$6.46
+2.70%
|
|
SLN
Silence Therapeutics plc
Silence Therapeutics directly develops RNA interference therapeutics (siRNA) as its core product modality.
|
$322.63M |
$6.88
+8.35%
|
|
ALLO
Allogene Therapeutics, Inc.
Primary focus on oncology therapies (cancer immunotherapies including ALLO-316, ALLO-329, ALPHA3 pipeline).
|
$315.07M |
$1.42
+4.04%
|
Showing page 12 of 25 (2438 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
